In NSCLC patients with brain metastases treated with icotinib, 12 EGFR mutation patients had a median survival time of 21.2 months, showing that icotinib can be beneficial for NSCLC patients with brain metastases [26]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.